38MO Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with pre-treated inoperable/metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Results from TROPION-Breast01 China cohort
Year: 2024
Type: article
Source: Annals of Oncology
Institutions: Sun Yat-sen University, Peking University People's Hospital, Sun Yat-sen University Cancer Center, Harbin Medical University, Third Affiliated Hospital of Harbin Medical University, Chinese PLA General Hospital, Tianjin Medical University Cancer Institute and Hospital, First Hospital of Jilin University, Central South University, Hunan Cancer Hospital, First Affiliated Hospital of Bengbu Medical College, Shandong Tumor Hospital, Shandong First Medical University, Jinan Central Hospital, Sir Run Run Shaw Hospital, Zhejiang Cancer Hospital, Zhejiang University, Affiliated Hospital of Hebei University, First Affiliated Hospital of Nanchang University, Third Hospital of Nanchang, Sichuan University, Changhai Hospital, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Chinese Academy of Medical Sciences & Peking Union Medical College, Cancer Hospital of Chinese Academy of Medical Sciences
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4405141710